Communication

Prof. Jae-Hyung Park and Dong-kyu Cho selected as regular members of KAST

The 'stem cell' challenge continues in the 'osteoarthritis' treatment market

Exostemtech applied for phase 1 clinical trial IND in Korea for an exosome-based osteoarthritis trea

Daewoong Pharmaceutical and ExostemTech, joint development agreement for exosome treatment

[Jump-Up Bio] Exostemtech said, "The first clinical trial in Korea next year...He's even going to ge

"The strength of Exostemtech is…World-class exosome mass production, analysis, and quality managemen

Exostemtech, a "exosome treatment," attracts 10 billion won in series B investment (Korea economy)

Exostemtech, Cancer Exosome Inhibitor Clinical Full-scale (The Bell)

Exostemtech approved phase 1 and 2a clinical trials for combination of Kitruda and Exosome inhibitor